A recent study published in the British Medical Journal by Vickers et al. titled “Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study”.
The study examined the associated between PSA level measured at age 40-55 and the subsequent risk of metastatic (advanced) prostate cancer and prostate cancer death.
Results found that PSA in early midlife was able to identify men at increased risk of developing advanced prostate cancer in late life.
